Discovery – Page 15 – Astex

Pyruvate Kinase M2: linking glycolysis to amino acid biosynthesis

24 November 2012/in 2012, Discovery

Pyruvate Kinase M2: linking glycolysis to amino acid biosynthesis

AACR: Pharmacodynamic and anti-tumor activity of fragment-derived inhibitors of MetAP2

24 October 2012/in 2012, Discovery

2012 TAT: Anti-Angiogenic Activity of Fragment-Derived Inhibitors of METAP2

10 March 2012/in 2012

2012 TAT: Anti-Angiogenic Activity of Fragment-Derived Inhibitors of METAP2

Alessandri et al. “Induction of Eosinophil Apoptosis by the Cyclin-Dependent Kinase Inhibitor AT7519 Promotes the Resolution of Eosinophil-Dominant Allergic Inflammation.” PLoS ONE 6, no. 9 2011: e25683. DOI: 10.1371/journal.pone.0025683.

29 November 2011/in 2011, Publications

Alessandri et al. “Induction of Eosinophil Apoptosis by the Cyclin-Dependent Kinase Inhibitor AT7519 Promotes the Resolution of Eosinophil-Dominant Allergic Inflammation.” PLoS ONE 6, no. 9 2011: e25683. DOI: 10.1371/journal.pone.0025683.

Arkenau et al. “A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.” Annals of Oncology 2011. DOI: 10.1093/annonc/mdr451.

29 November 2011/in 2011, Publications

Arkenau et al. “A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.” Annals of Oncology 2011. DOI: 10.1093/annonc/mdr451.

Brito et al. “Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.” Leukemia Research 35, no. 9 2011: 1233-1240. DOI: 10.1016/j.leukres.2011.01.011.

29 November 2011/in 2011, Publications

Brito et al. “Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.” Leukemia Research 35, no. 9 2011: 1233-1240. DOI: 10.1016/j.leukres.2011.01.011.

Heightman, Tom D. “Therapeutic prospects for epigenetic modulation.” Expert Opinion on Therapeutic Targets 15, no. 6 2011: 729-740. DOI: 10.1517/14728222.2011.561786.

29 November 2011/in 2011, Publications

Heightman, Tom D. “Therapeutic prospects for epigenetic modulation.” Expert Opinion on Therapeutic Targets 15, no. 6 2011: 729-740. DOI: 10.1517/14728222.2011.561786.

Mahadevan et al. “A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.” Annals of Oncology 22, no. 9 2011: 2137-2143. DOI: 10.1093/annonc/mdq734.

29 November 2011/in 2011, Publications

Mahadevan et al. “A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.” Annals of Oncology 22, no. 9 2011: 2137-2143. DOI: 10.1093/annonc/mdq734.

Paul N. Mortenson and Christopher W. Murray. “Assessing the lipophilicity of fragments and early hits.” Journal of Computer-Aided Molecular Design 25, no. 7 2011: 663-667. DOI: 10.1007/s10822-011-9435-z.

29 November 2011/in 2011, Publications

Paul N. Mortenson and Christopher W. Murray. “Assessing the lipophilicity of fragments and early hits.” Journal of Computer-Aided Molecular Design 25, no. 7 2011: 663-667. DOI: 10.1007/s10822-011-9435-z.

Podesta et al. “Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.” Leukemia Research 35, no. 9 2011: 1273-1275. DOI: 10.1016/j.leukres.2011.05.022.

29 November 2011/in 2011, Publications

Podesta et al. “Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.” Leukemia Research 35, no. 9 2011: 1273-1275. DOI: 10.1016/j.leukres.2011.05.022.